
Three observable trends based on the clinical trial data.

1. During the treatment period Capomulin is more effective to reduce the tumor volume comparing with the other drug.

2. Metastatic spread was less during the treatment period for Capomulin comparitive to the other drug.

3. Survival rate is more for Capomulin than the other drugs during the treatment.